3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 4
1
Phase 3
1
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
5
Endocrine
5
CNS
3
Thoracic
2
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Neuroendocrine Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Gemcitabine
153
Oxaliplatin
124
Fluorouracil
108
Capecitabine
105
pembrolizumab
92
Bevacizumab
79
Leucovorin
76
Irinotecan
72
Nivolumab
70
130-nm albumin-bound paclitaxel
68
Paclitaxel
62
Cisplatin
62
Cetuximab
60
Cyclophosphamide
47
Albumin-Bound Paclitaxel
45
Radiotherapy
39
Docetaxel
36
durvalumab
33
Sorafenib
32
Taxes
29
Carboplatin
27
fludarabine
26
tislelizumab
25
Drug Therapy
25
atezolizumab
23
Folfox protocol
23
regorafenib
20
lenvatinib
19
Ipilimumab
19
sintilimab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
lutetium Lu 177 dotatate
×
Gastrointestinal
×
Clear all
NCT04614766
2024-04-29
SPORE-3
University of Iowa
Phase 1/2
Withdrawn